Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.

Zhang, Min and Fu, Wuxia and Prabhu, Sharmila and Moore, James C and Ko, Je and Kim, Jung Woo and Druker, Brian J and Trapp, Valerie and Fruehauf, John and Gram, Hermann and Fan, Hung Y and Ong, S Tiong (2008) Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Molecular and Cellular Biology, 28 (20). pp. 6496-6509. ISSN 1098-5549

Abstract

Dysregulated mRNA translation is implicated in the pathogenesis of many human cancers including chronic myelogenous leukemia (CML). Because our prior work has specifically implicated translation initiation in CML, we tested compounds that could modulate translation initiation and polysomal mRNA assembly. Here, we evaluated the activity of one such compound, CGP57380, against CML cells and explored its mechanisms of action. First, using polysomal mRNA profiles, we found that imatinib and CGP57380 could independently, and cooperatively, impair polysomal mRNA loading. Imatinib and CGP57380 also synergistically inhibited the growth of Ba/F3-Bcr-Abl and K562 cells via impaired cell cycle entry and increased apoptosis. Mechanistically, CGP57380 inhibited efficient polysomal assembly via two processes. First, it enhanced imatinib-mediated inhibition of eukaryotic initiation factor 4F induction, and second, it independently impaired phosphorylation of ribosomal protein S6 on the preinitiation complex. We also identified multiple substrates of the mTOR, Rsk, and Mnk kinases as targets of CGP57380. Finally, we found a novel negative-feedback loop to the mitogen-activated protein kinase/Mnk pathway that is triggered by CGP57380 and demonstrated that an interruption of the loop further increased the activity of the combination against imatinib-sensitive and -resistant CML cells. Together, this work supports the inhibition of translation initiation as a therapeutic strategy for treating cancers fueled by dysregulated translation.

Item Type: Article
Related URLs:
Additional Information: author can archive post-print (ie final draft post-refereeing); but on personal or university-hosted websites only
Related URLs:
Date Deposited: 14 Dec 2009 13:49
Last Modified: 31 Jan 2013 00:58
URI: https://oak.novartis.com/id/eprint/1110

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.